Evidence map›Paper›PMID 37051070›Full record

ReviewOxford open immunology2023

Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.

Kriti Negi, Meetu Agarwal, Isha Pahuja, Bhavya Bhardwaj, Mansi Rawat, Ashima Bhaskar, Ved Prakash Dwivedi

Abstract readReview
In one paragraph

Review in Oxford open immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Association Between Genetic Variants inDiagnostics (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kriti NegiImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Meetu AgarwalDepartment of Molecular Medicine, Jamia Hamdard University, New Delhi, India.
Isha PahujaImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Bhavya BhardwajImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Mansi RawatImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Ashima BhaskarImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Ved Prakash DwivediImmunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.ORCID https://orcid.org/0000-0003-4321-2567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes lethal coronavirus disease (COVID-19). SARS-CoV-2 has been the chief source of threat to public health and safety from 2019 to the present. SARS-CoV-2 caused a sudden and significant rise in hospitalization due to respiratory issues and pneumonia. We are consistently uncovering new information about SARS-CoV-2, and yet so much is to explore to implement efficient interventions to combat the emergent variants and spread of the ongoing pandemic. Information regarding the existing COVID-19 pandemic is streamlining continuously. However, clinical symptoms of SARS-CoV-2 infections spanning from asymptomatic infection to severe death-instigating disease remain consistent with preliminary reports. In this review, we have briefly introduced highlights of the COVID-19 pandemic and features of SARS-CoV-2. We have focused on current knowledge of innate and adaptive immune responses during SARS-CoV-2 infections and persisting clinical features of recovered patients. Furthermore, we have discussed how these immune responses are not tightly regulated and imbalance can direct the latter phases of COVID-19, long-COVID symptoms, and cause detrimental immunopathogenesis. COVID-19 vaccines are also discussed in detail to describe the efforts going around the world to control and prevent the infection. Overall, we have summarized the current knowledge on the immunology of SARS-CoV-2 infection and the utilization of that knowledge in the development of a suitable COVID-19 therapeutics and vaccines.

Indexed as

COVID-19diagnosisimmunotherapySARS-CoV-2vaccines

Identifiers

PMID37051070
PMCPMC9985161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.